{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:29:37Z","timestamp":1740122977247,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T00:00:00Z","timestamp":1530316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10928-018-9598-5","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T08:46:14Z","timestamp":1530348374000},"page":"679-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Joint longitudinal model development: application to exposure\u2013response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7812-2778","authenticated-orcid":false,"given":"Chuanpu","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,30]]},"reference":[{"key":"9598_CR1","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1038\/psp.2014.15","volume":"3","author":"C Hu","year":"2014","unstructured":"Hu C (2014) Exposure-response modeling of clinical end points using latent variable indirect response models. CPT 3:e117. \n                    https:\/\/doi.org\/10.1038\/psp.2014.15","journal-title":"CPT"},{"key":"9598_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9534-0","author":"C Hu","year":"2017","unstructured":"Hu C, Zhou H, Sharma A (2017) Landmark and longitudinal exposure-response analyses in drug development. J Pharmacokinet Pharmacodyn. \n                    https:\/\/doi.org\/10.1007\/s10928-017-9534-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"9598_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/BF02353483","volume":"24","author":"A Sharma","year":"1996","unstructured":"Sharma A, Jusko WJ (1996) Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 24(6):611\u2013635","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"9598_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727\u2013735","journal-title":"Arthritis Rheum"},{"key":"9598_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10928-007-9080-2","volume":"35","author":"MM Hutmacher","year":"2008","unstructured":"Hutmacher MM, Krishnaswami S, Kowalski KG (2008) Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35:139\u2013157","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9598_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10928-010-9162-4","volume":"37","author":"C Hu","year":"2010","unstructured":"Hu C, Xu Z, Rahman MU, Davis HM, Zhou H (2010) A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn 37(4):309\u2013321","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9598_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10928-012-9288-7","volume":"40","author":"C Hu","year":"2013","unstructured":"Hu C, Xu Z, Mendelsohn A, Zhou H (2013) Latent variable indirect response modeling of categorical endpoints representing change from baseline. J Pharmacokinet Pharmacodyn 40(1):81\u201391","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9598_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10928-011-9191-7","volume":"38","author":"C Hu","year":"2011","unstructured":"Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician\u2019s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237\u2013260","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9598_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10928-011-9205-5","volume":"38","author":"C Hu","year":"2011","unstructured":"Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497\u2013517","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9598_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10928-015-9453-x","volume":"43","author":"C Hu","year":"2016","unstructured":"Hu C, Zhou H (2016) Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis. J Pharmacokinet Pharmacodyn 43(1):45\u201354","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9598_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9531-3","author":"C Hu","year":"2017","unstructured":"Hu C, Randazzo B, Sharma A, Zhou H (2017) Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. J Pharmacokinet Pharmacodyn. \n                    https:\/\/doi.org\/10.1007\/s10928-017-9531-3","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"9598_CR12","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73(9):1616\u20131625. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-205137","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"9598_CR13","first-page":"812","volume":"10","author":"C Hu","year":"2011","unstructured":"Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(7):812\u2013822","journal-title":"Pharm Stat"},{"issue":"7","key":"9598_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1177\/0091270008318670","volume":"48","author":"C Hu","year":"2008","unstructured":"Hu C, Zhou H (2008) An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol 48(7):812\u2013822. \n                    https:\/\/doi.org\/10.1177\/0091270008318670","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9598_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387\u2013404","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9598_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10928-014-9366-0","volume":"41","author":"C Hu","year":"2014","unstructured":"Hu C, Szapary PO, Mendelsohn AM, Zhou H (2014) Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint. J Pharmacokinet Pharmacodyn 41(4):335\u2013349. \n                    https:\/\/doi.org\/10.1007\/s10928-014-9366-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9598_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10928-014-9385-x","volume":"41","author":"L Ma","year":"2014","unstructured":"Ma L, Zhao L, Xu Y, Yim S, Doddapaneni S, Sahajwalla CG, Wang Y, Ji P (2014) Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation. J Pharmacokinet Pharmacodyn 41(5):537\u2013543. \n                    https:\/\/doi.org\/10.1007\/s10928-014-9385-x","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9598_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10928-009-9128-6","volume":"36","author":"S Woo","year":"2009","unstructured":"Woo S, Pawaskar D, Jusko WJ (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36:381\u2013405","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9598_CR19","volume-title":"NONMEM user\u2019s guides (1989-2009)","author":"SL Beal","year":"2009","unstructured":"Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user\u2019s guides (1989-2009). Icon Development Solutions, Ellicott City"},{"issue":"3","key":"9598_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5414\/CP201785","volume":"51","author":"Y Zhuang","year":"2013","unstructured":"Zhuang Y, Xu Z, de Vries DE, Wang Q, Shishido A, Comisar C, Ford JA, Keen M, Achira M, Tsukamoto Y, Petty KJ, Davis HM, Zhou H (2013) Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther 51(3):187\u2013199. \n                    https:\/\/doi.org\/10.5414\/CP201785","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"9598_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558\u2013569. \n                    https:\/\/doi.org\/10.1208\/s12248-009-9133-0","journal-title":"AAPS J"},{"issue":"9","key":"9598_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/jcph.967","volume":"57","author":"L Li","year":"2017","unstructured":"Li L, Zhang Y, Ma L, Ji P, Yim S, Chowdhury BA, Doddapaneni S, Liu J, Wang Y, Sahajwalla C (2017) Exposure-response modeling and power analysis of components of ACR response criteria in rheumatoid arthritis (Part 2: continuous model). J Clin Pharmacol 57(9):1107\u20131125. \n                    https:\/\/doi.org\/10.1002\/jcph.967","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"9598_CR23","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/sim.4155","volume":"30","author":"MM Hutmacher","year":"2011","unstructured":"Hutmacher MM, French JL, Krishnaswami S, Menon S (2011) Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med 30(9):935\u2013949. \n                    https:\/\/doi.org\/10.1002\/sim.4155","journal-title":"Stat Med"},{"issue":"1","key":"9598_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1037\/1082-989X.11.1.54","volume":"11","author":"M Smithson","year":"2006","unstructured":"Smithson M, Verkuilen J (2006) A better lemon squeezer? Maximumlikelihood regression with beta-distributed dependent variables. Psychol Methods 11(1):54\u201371","journal-title":"Psychol Methods"},{"issue":"9","key":"9598_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcph.891","volume":"57","author":"L Li","year":"2017","unstructured":"Li L, Zhang Y, Ma L, Ji P, Yim S, Chowdhury B, Doddapaneni S, Liu J, Wang Y, Sahajwalla C (2017) Exposure-response modeling and power analysis of components of ACR response criteria in rheumatoid arthritis (Part 1: binary model). J Clin Pharmacol 57(9):1097\u20131106. \n                    https:\/\/doi.org\/10.1002\/jcph.891","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"9598_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/psp4.12015","volume":"4","author":"RV Overgaard","year":"2015","unstructured":"Overgaard RV, Ingwersen SH, Tornoe CW (2015) Establishing good practices for exposure-response analysis of clinical endpoints in drug development. CPT 4(10):565\u2013575. \n                    https:\/\/doi.org\/10.1002\/psp4.12015","journal-title":"CPT"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9598-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T19:04:50Z","timestamp":1561835090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9598-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["9598"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9598-5","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2018,6,30]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}